Oncomine Breast cfTNA Assay Test
Cost: AED 9600.0
Symptoms, Diagnosis, and Test Details
The Oncomine Breast cfTNA Assay Test is a diagnostic test that is used to detect genetic mutations in cell-free tumor DNA (cfTNA) from the blood of patients with breast cancer. This test analyzes 49 genes commonly mutated in breast cancer, including BRCA1, BRCA2, and TP53, using next-generation sequencing technology.
The test is designed to help physicians identify patients who may benefit from targeted therapies or clinical trials based on their specific genetic mutations. It can also be used to monitor treatment response and disease progression over time.
Unlike traditional tissue biopsies, the Oncomine Breast cfTNA Assay Test is a minimally invasive alternative that does not require painful procedures or recovery time. Additionally, it is faster and less expensive than traditional genetic testing methods, allowing for more efficient and personalized treatment options for patients with breast cancer.
Test Components
- Streak Tube
Price
AED 9600.0
Sample Condition
Peripheral blood (10 ml.)
Report Delivery
2-3 weeks
Method
Next-Generation Sequencing (NGS)
Test Type
Genetics
Doctor
General Physician
Test Department
Pre Test Information
The Oncomine Breast cfTNA Assay Test can be done with a doctor’s prescription. However, it is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Name | Oncomine Breast cfTNA Assay Test |
---|---|
Components | Streak Tube |
Price | 9600.0 AED |
Sample Condition | Peripheral blood (10 ml.) |
Report Delivery | 2-3 weeks |
Method | NGS |
Test type | Genetics |
Doctor | General Physician |
Test Department: | |
Pre Test Information | Oncomine Breast cfTNA Assay can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
Test Details | The Oncomine Breast cfTNA Assay is a diagnostic test that is used to detect genetic mutations in cell-free tumor DNA (cfTNA) from the blood of patients with breast cancer. The assay uses next-generation sequencing technology to analyze 49 genes that are commonly mutated in breast cancer, including BRCA1, BRCA2, and TP53. The test is designed to help physicians identify patients who may benefit from targeted therapies or clinical trials based on their specific genetic mutations. It can also be used to monitor treatment response and disease progression over time. The Oncomine Breast cfTNA Assay is a minimally invasive alternative to traditional tissue biopsies, which can be painful and require recovery time. It is also faster and less expensive than traditional genetic testing methods, allowing for more efficient and personalized treatment options for patients with breast cancer. |